News | December 30, 2022
The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people with haemophilia A in locations where there is little to no access to haemophilia treatment
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
Subscribe To Our Newsletter & Stay Updated
